tradingkey.logo

GeneDx Holdings Corp

WGS
128.060USD
-2.290-1.76%
Close 11/14, 16:00ETQuotes delayed by 15 min
3.70BMarket Cap
1776.10P/E TTM

GeneDx Holdings Corp

128.060
-2.290-1.76%

More Details of GeneDx Holdings Corp Company

GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. GeneDx utilizes an integrated portfolio of laboratory processes, software tools, and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. GeneDx provides a variety of genetic diagnostic tests, screening solutions, and information. The Legacy Sema4 diagnostics segment provides reproductive and women's health and somatic oncology diagnostic testing and screening products.

GeneDx Holdings Corp Info

Ticker SymbolWGS
Company nameGeneDx Holdings Corp
IPO dateSep 04, 2020
CEOMs. Katherine A. Stueland
Number of employees1000
Security typeOrdinary Share
Fiscal year-endSep 04
Address333 Ludlow Street
CitySTAMFORD
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code06902
Phone18887291206
Websitehttps://sema4.com/
Ticker SymbolWGS
IPO dateSep 04, 2020
CEOMs. Katherine A. Stueland

Company Executives of GeneDx Holdings Corp

Name
Name/Position
Position
Shareholding
Change
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
223.99K
+6.12%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
33.16K
+63.87%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
4.12K
+9.73%
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
3.58K
-82.23%
Dr. Thomas Fuchs
Dr. Thomas Fuchs
Director
Director
--
--
Dr. Bryan Dechairo
Dr. Bryan Dechairo
Chief Operating Officer
Chief Operating Officer
--
--
Ms. Katherine A. Stueland
Ms. Katherine A. Stueland
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jason Michael Ryan, CPA
Mr. Jason Michael Ryan, CPA
Chairman of the Board
Chairman of the Board
--
--
Mr. Eli D. Casdin
Mr. Eli D. Casdin
Independent Director
Independent Director
--
--
Mr. Richard C. (Rick) Pfenniger, Jr.
Mr. Richard C. (Rick) Pfenniger, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Joshua Ruch
Mr. Joshua Ruch
Independent Director
Independent Director
223.99K
+6.12%
Dr. Emily M. Leproust, Ph.D.
Dr. Emily M. Leproust, Ph.D.
Independent Director
Independent Director
33.16K
+63.87%
Mr. Kevin Feeley
Mr. Kevin Feeley
Chief Financial Officer
Chief Financial Officer
4.12K
+9.73%
Mr. Keith A. Meister
Mr. Keith A. Meister
Independent Director
Independent Director
3.58K
-82.23%
Dr. Thomas Fuchs
Dr. Thomas Fuchs
Director
Director
--
--
Dr. Bryan Dechairo
Dr. Bryan Dechairo
Chief Operating Officer
Chief Operating Officer
--
--

Revenue Breakdown

Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Patients with third party insurance
81.10M
78.98%
Institutional customers
18.38M
17.90%
Other
2.87M
2.79%
Self pay patients
339.00K
0.33%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Patients with third party insurance
81.10M
78.98%
Institutional customers
18.38M
17.90%
Other
2.87M
2.79%
Self pay patients
339.00K
0.33%

Shareholding Stats

Updated: 2 hours ago
Updated: 2 hours ago
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Corvex Management LP
10.58%
Casdin Capital, LLC
10.54%
Icahn School of Medicine at Mount Sinai
4.75%
OPKO Health Inc
4.74%
BlackRock Institutional Trust Company, N.A.
4.56%
Other
64.83%
Shareholders
Shareholders
Proportion
Corvex Management LP
10.58%
Casdin Capital, LLC
10.54%
Icahn School of Medicine at Mount Sinai
4.75%
OPKO Health Inc
4.74%
BlackRock Institutional Trust Company, N.A.
4.56%
Other
64.83%
Shareholder Types
Shareholders
Proportion
Hedge Fund
36.29%
Investment Advisor/Hedge Fund
35.91%
Investment Advisor
30.37%
Corporation
10.65%
Research Firm
6.55%
Individual Investor
1.62%
Pension Fund
0.78%
Venture Capital
0.54%
Bank and Trust
0.49%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
446
32.52M
112.51%
-918.42K
2025Q2
397
34.23M
119.24%
+1.02M
2025Q1
398
32.79M
115.46%
-47.86K
2024Q4
341
29.17M
104.22%
+1.72M
2024Q3
289
26.18M
97.50%
+377.48K
2024Q2
262
24.98M
95.33%
+588.25K
2024Q1
260
22.13M
86.19%
+1.41M
2023Q4
271
20.57M
80.67%
-567.28K
2023Q3
283
21.68M
85.29%
-751.02K
2023Q2
291
21.85M
86.03%
-864.88K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Corvex Management LP
3.06M
10.65%
--
--
Aug 22, 2025
Casdin Capital, LLC
3.05M
10.6%
-461.51K
-13.16%
Aug 22, 2025
Icahn School of Medicine at Mount Sinai
1.37M
4.78%
-1.35M
-49.50%
Feb 21, 2025
OPKO Health Inc
1.37M
4.77%
-800.83K
-36.88%
Nov 20, 2024
BlackRock Institutional Trust Company, N.A.
1.28M
4.45%
+241.28K
+23.25%
Jun 30, 2025
William Blair Investment Management, LLC
1.63M
5.68%
+442.41K
+37.21%
Jun 30, 2025
Pentwater Capital Management LP
1.22M
4.25%
+1.19M
+3712.50%
Jun 30, 2025
The Vanguard Group, Inc.
1.18M
4.09%
+148.96K
+14.50%
Jun 30, 2025
Goldman Sachs & Company, Inc.
973.26K
3.39%
-59.05K
-5.72%
Jun 30, 2025
Oracle Investment Management, Inc.
922.45K
3.21%
-47.50K
-4.90%
Jun 30, 2025
View more

Related ETFs

Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Global X Genomics & Biotechnology ETF
3.13%
Franklin Genomic Advancements ETF
2.07%
SPDR S&P Health Care Services ETF
1.66%
Simplify Health Care ETF
1.31%
Innovator IBD 50 Fund ETF
1.27%
Harbor Health Care ETF
1.27%
Invesco Dorsey Wright Healthcare Momentum ETF
1%
Main Thematic Innovation ETF
0.8%
First Trust Small Cap Growth AlphaDEX Fund
0.65%
ARK Genomic Revolution ETF
0.61%
View more
Global X Genomics & Biotechnology ETF
Proportion3.13%
Franklin Genomic Advancements ETF
Proportion2.07%
SPDR S&P Health Care Services ETF
Proportion1.66%
Simplify Health Care ETF
Proportion1.31%
Innovator IBD 50 Fund ETF
Proportion1.27%
Harbor Health Care ETF
Proportion1.27%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1%
Main Thematic Innovation ETF
Proportion0.8%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.65%
ARK Genomic Revolution ETF
Proportion0.61%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Date
Type
Ratio
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
Apr 28, 2023
Merger
33→1
KeyAI